Patient-Centricity in Psychedelic Treatment: Why the Patient Matters

In recent years, there has been renewed interest in psychedelic treatment for a variety of medical conditions ranging from depression to trauma, and even dementia, which has left countless people searching for real recovery. This exciting research is challenging the limits of what’s possible. Psychedelic compounds, once misunderstood or dismissed, are now being studied for their ability to promote neuroplasticity, neurogenesis, and reduction in inflammation.

In this episode of Trending Health, we’re joined by three individuals who are passionate about the growing clinical utility of psychedelic treatments. However, with these treatments, it is critical to think about how to put the patient in the middle and engaged with their treatment to help ensure optimal outcomes:

• Varun Renjen, a partner at Inizio Putnam and a physician who has been supporting biopharma clients as a strategy consultant for the past 15 years; especially in neurological diseases;
• Steve Levine, Chief Patient Officer at Compass Pathways and board-certified psychiatrist who has spent his career working to improve people’s lives through creating access to innovation in mental health;
• Daniel Carcillo, a former NHL hockey player who developed Traumatic Brain Injury (TBI) and depression from the sport who has been successfully treated with psychedelic therapy as a patient and is an advocate for access to psychedelic treatment for brain injury

Tags: healthcare, psychedelics, psilocybin, mushrooms, concussions, traumatic brain injuries, depression, mental health, medical affairs

Panel – Varun Renjen, Steve Levine, Daniel Carcillo

Recording & Editing – Mike Liberto

For additional discussion, please contact us at TrendingHealth.com.